Literature DB >> 19669780

Management of submacular hemorrhage with intravitreal versus subretinal injection of recombinant tissue plasminogen activator.

Jost Hillenkamp1, Vladimir Surguch, Carsten Framme, Veit-Peter Gabel, Helmut G Sachs.   

Abstract

AIM: To compare the efficacy of pars plana vitrectomy (ppV) with intravitreal injection of recombinant tissue plasminogen activator (rtPA) and gas versus ppV with subretinal injection of rtPA and intravitreal injection of gas.
METHODS: Nonrandomized, retrospective, interventional, comparative consecutive series including 47 patients with submacular hemorrhage. Eighteen patients were treated with ppV, intravitreal injection of rtPA and 20% SF6 gas [group A: mean age 78 years, mean duration of symptoms 6.6 days, 15 age-related macular degeneration (AMD), three retinal arterial macroaneurysm (RAMA)]. Twenty-nine patients were treated with ppV, subretinal injection of rtPA and intravitreal injection of SF6 gas (group B: mean age 75 years, mean duration of symptoms 5.9 days, 26 AMD, two RAMA, one blunt ocular trauma). The main outcome measure was complete displacement of submacular hemorrhage from the fovea.
RESULTS: Complete displacement of submacular hemorrhage was achieved in less patients in group A (22%) than in group B (55%) (p = 0.025). In group A, mean best-corrected visual acuity (BCVA) change was logMAR -0.14, standard deviation (SD) = 0.64, and in group B logMAR -0.32, SD = 0.68 without statistically significant difference between the two groups (p = 0.2, Mann-Whitney test). Complications (retinal detachment, vitreous hemorrhage, and recurrence of submacular hemorrhage) were more frequent in group B than in group A.
CONCLUSION: ppV with subretinal injection of rtPA and intravitreal injection of gas was more effective than ppV with intravitreal injection of rtPA and gas in terms of complete displacement of submacular hemorrhage; however, it may be associated with a higher rate of postoperative complications. Functional improvement in the majority of patients suggests the absence of direct retinal toxicity of subretinally applied rtPA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19669780     DOI: 10.1007/s00417-009-1158-7

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  29 in total

1.  Vitreous surgery for hemorrhagic and fibrous complications of age-related macular degeneration.

Authors:  E de Juan; R Machemer
Journal:  Am J Ophthalmol       Date:  1988-01-15       Impact factor: 5.258

2.  A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits.

Authors:  M Kamei; K Misono; H Lewis
Journal:  Am J Ophthalmol       Date:  1999-12       Impact factor: 5.258

3.  The rate and source of albumin entry into saline-filled experimental retinal detachments.

Authors:  A Takeuchi; G Kricorian; X Y Yao; J W Kenny; M F Marmor
Journal:  Invest Ophthalmol Vis Sci       Date:  1994-10       Impact factor: 4.799

4.  Fibrin directs early retinal damage after experimental subretinal hemorrhage.

Authors:  C A Toth; L S Morse; L M Hjelmeland; M B Landers
Journal:  Arch Ophthalmol       Date:  1991-05

5.  Surgical removal of massive subretinal hemorrhage associated with age-related macular degeneration.

Authors:  J F Vander; J L Federman; C Greven; M M Slusher; V P Gabel
Journal:  Ophthalmology       Date:  1991-01       Impact factor: 12.079

6.  Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement.

Authors:  A S Hassan; M W Johnson; T E Schneiderman; C D Regillo; P E Tornambe; L S Poliner; B A Blodi; S G Elner
Journal:  Ophthalmology       Date:  1999-10       Impact factor: 12.079

7.  [Subretinal lavage in fresh hemorrhage in macular degeneration].

Authors:  V P Gabel
Journal:  Fortschr Ophthalmol       Date:  1991

8.  Tissue plasminogen activator treatment of experimental subretinal hemorrhage.

Authors:  M W Johnson; K R Olsen; E Hernandez
Journal:  Retina       Date:  1991       Impact factor: 4.256

9.  Massive hemorrhage complicating age-related macular degeneration. Clinicopathologic correlation and role of anticoagulants.

Authors:  F el Baba; W H Jarrett; T S Harbin; S L Fine; R G Michels; A P Schachat; W R Green
Journal:  Ophthalmology       Date:  1986-12       Impact factor: 12.079

10.  Tissue plasminogen activating factor assisted removal of subretinal hemorrhage.

Authors:  G A Peyman; N C Nelson; W Alturki; K J Blinder; C L Paris; U R Desai; C A Harper
Journal:  Ophthalmic Surg       Date:  1991-10
View more
  40 in total

1.  [Subretinal co-application of rtPA and bevacizumab for exudative AMD with submacular hemorrhage. Compatibility and clinical long-term results].

Authors:  J Hillenkamp; A Klettner; S Puls; F Treumer; J Roider
Journal:  Ophthalmologe       Date:  2012-07       Impact factor: 1.059

2.  Vitrectomy with subretinal tissue plasminogen activator and ranibizumab for submacular haemorrhages secondary to age-related macular degeneration: retrospective case series of 45 consecutive cases.

Authors:  J J González-López; G McGowan; E Chapman; D Yorston
Journal:  Eye (Lond)       Date:  2016-04-08       Impact factor: 3.775

3.  [Retinal laser treatment-avoiding mistakes].

Authors:  Carsten Framme; Hans Hoerauf; Joachim Wachtlin; Ingo Volkmann; Martin Bartram; Bernd Junker; Nicolas Feltgen
Journal:  Ophthalmologe       Date:  2020-02       Impact factor: 1.059

4.  Retinal sensitivity after displacement of submacular hemorrhage due to polypoidal choroidal vasculopathy: effectiveness and safety of subretinal tissue plasminogen activator.

Authors:  Shuhei Kimura; Yuki Morizane; Ryo Matoba; Mio Hosokawa; Yusuke Shiode; Masayuki Hirano; Shinichiro Doi; Shinji Toshima; Kosuke Takahashi; Mika Hosogi; Atsushi Fujiwara; Fumio Shiraga
Journal:  Jpn J Ophthalmol       Date:  2017-08-23       Impact factor: 2.447

5.  The role of pigment epithelial detachment in AMD with submacular hemorrhage treated with vitrectomy and subretinal co-application of rtPA and anti-VEGF.

Authors:  F Treumer; S Wienand; K Purtskhvanidze; J Roider; J Hillenkamp
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-03-09       Impact factor: 3.117

6.  Early treatment of acute submacular haemorrhage secondary to wet AMD using intravitreal tissue plasminogen activator, C3F8, and an anti-VEGF agent.

Authors:  S R de Silva; M S Bindra
Journal:  Eye (Lond)       Date:  2016-04-15       Impact factor: 3.775

7.  Subretinal injection of recombinant tissue plasminogen activator for submacular hemorrhage associated with ruptured retinal arterial macroaneurysm.

Authors:  Makoto Inoue; Fumio Shiraga; Yukari Shirakata; Yuki Morizane; Shuhei Kimura; Akito Hirakata
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-11-25       Impact factor: 3.117

8.  Planned foveal detachment technique for the resolution of diffuse diabetic macular edema.

Authors:  Yuki Morizane; Shuhei Kimura; Mio Hosokawa; Yusuke Shiode; Masayuki Hirano; Shinichiro Doi; Mika Hosogi; Atsushi Fujiwara; Yasushi Inoue; Fumio Shiraga
Journal:  Jpn J Ophthalmol       Date:  2015-07-30       Impact factor: 2.447

9.  Recombinant tissue plasminogen activator, vitrectomy, and gas for recent submacular hemorrhage displacement due to retinal macroaneurysm.

Authors:  Elsbeth J T van Zeeburg; Matteo G Cereda; Jan C van Meurs
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-08-04       Impact factor: 3.117

10.  Incidence of submacular haemorrhage (SMH) in Scotland: a Scottish Ophthalmic Surveillance Unit (SOSU) study.

Authors:  Aws Al-Hity; David H Steel; David Yorston; David Gilmour; Zachariah Koshy; David Young; Jost Hillenkamp; Gerard McGowan
Journal:  Eye (Lond)       Date:  2018-10-29       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.